There is a number you memorized once, at a counter, on a bad afternoon, and have been paying ever since.

Maybe it was $61. Maybe $148. You remember the small internal flinch, the way you said "yeah, that's fine" in a voice that meant it wasn't. And then something merciful happened: you stopped noticing. The charge became furniture. It showed up every month like the electric bill, and you paid it the way you pay the electric bill — without asking whether the rate had changed.

Here is the uncomfortable part. For a great many prescriptions, the rate did change. It fell. It sometimes fell by most of its value, in a way that was entirely predictable months before it happened, and nobody called you. There is no letter from your pharmacy that says the drug you take got cheap this spring. There is only the same number on the same receipt, and a person who stopped looking a long time ago.

The day the patent expires is not the day the price drops

Almost everyone believes the story runs like this: brand drug is expensive, patent expires, generic arrives, price collapses. Three beats, clean and satisfying.

The real sequence has a step hidden inside it, and that step is where your money goes.

When Congress wrote the 1984 Hatch-Waxman Act — formally, the Drug Price Competition and Patent Term Restoration Act — it needed to solve a problem. Challenging a drug patent is expensive and slow. If any generic manufacturer could free-ride on the first one's litigation, nobody would go first. So Congress built a bribe into the law: the first company to file an abbreviated application and formally challenge the brand's patents is granted 180 days of generic exclusivity. For six months, in most cases, it is the only true generic on the shelf.

A monopolist with one competitor does not slash prices. It shades them. The first generic typically launches at a modest discount to the brand — enough to win the switch, nowhere near enough to feel like relief. The brand company, meanwhile, often responds by licensing an authorized generic: its own pill, same factory, in a plain wrapper, sold under a generic label during the exclusivity window. Two sellers, one of whom is the brand in a disguise. The price does what a two-seller price does. It sags. It does not fall.

Then the window closes, and the sequence you were promised finally begins.

Price is a function of how many people make the pill

The FDA has studied this directly, comparing generic prices to the brand price as manufacturers pile in. The pattern is not subtle. With a single generic competitor, the price barely moves from the brand's. With a second, it drops to roughly half. And it keeps sliding as the third, fourth, and fifth manufacturers arrive — the steepest declines showing up not at the moment of "generic availability" but months later, once the market is genuinely crowded.

This is the whole mechanism, and it is worth saying plainly because it inverts the thing most people believe: the word "generic" on your bottle tells you almost nothing about the price. The number of companies making it tells you almost everything.

Which means the question is not is there a generic? It is how long has the generic been generic?

A drug six months into its generic life and a drug six years into it are different economic animals, even when they are chemically identical. The first is a near-monopoly wearing a generic label. The second is a commodity, priced like flour. Somewhere between those two states, your prescription quietly crossed over — and unless you happened to reprice it that month, you are still paying near-monopoly rates for flour.

Why you never noticed

The behavioral science here is old and well-established, and it is not flattering.

Tversky and Kahneman described anchoring: once a number is in your head, every subsequent judgment drags toward it. The $148 you paid on that first bad afternoon didn't just describe the price. It became your model of the price. When a friend mentions their prescription costs $9, some part of you assumes theirs is a different, lesser drug, because $148 is what this drug is.

Stacked on top of that is something simpler: you are not searching. Price comparison is a search behavior, and search behavior has a shutoff valve. We stop searching when we believe the information is stable. Gas prices, we check — they visibly move. Prescription prices, we do not — the receipt looks the same every month, so the world looks static. The information is moving. The feedback is not.

And pharmacies have no obligation, and no particular incentive, to volunteer that the cash price of the thing in your bag fell 70% while your copay sat still. Your copay is set by a tier in a formulary. Tiers are revised on an annual cycle, by committee, with a lag. The underlying acquisition cost can drop for a year before that tier notices — and in some cases, the fixed copay you're proudly "using your insurance" to pay is now well above what the drug costs cash.

The tell, and how to read it

The good news is that this is one of the few places in American healthcare where the truth is public and free.

CMS publishes NADAC — the National Average Drug Acquisition Cost — a weekly survey of what retail pharmacies actually pay their wholesalers for a given drug, by NDC. It is not what you'll be charged. It's the floor beneath what you'll be charged, and it is updated often enough to show a generic cliff as it happens, week by week, months before it reaches a formulary tier.

If your drug went generic in the last year, its NADAC is a live picture of a market filling up. If it's been generic for five years, the NADAC is probably a few cents a tablet, and if you're paying $61, you now know something specific and actionable: the gap is not the drug. The gap is the markup.

One honest caveat, because this cuts both ways. Generic prices don't only fall. Manufacturing shortages and market exits can push a commodity generic sharply back up, and when that happens the same weekly data shows the climb. The point is not that cheaper is inevitable. The point is that the number is moving, and you are treating it as fixed.

Your next moves

  • Find out how old the generic is. Ask your pharmacist one sentence: "How long has this been available as a generic, and how many manufacturers make it now?" They usually know, and it takes ten seconds. "Just went generic" is a signal to recheck in six months. "Everybody makes it" is a signal that a high price is markup, not scarcity.
  • Put a recheck date on the calendar right now. For any drug that went generic within the past year, set a reminder for six months and twelve months out. Those are the two moments the price is most likely to have moved. The reminder is doing the work your attention will not.
  • Look up the cash price before your next refill — not after. Compare the national average acquisition cost to what you actually paid last month. If they're a factor apart, you have a specific number to bring to a specific conversation.
  • Ask whether the cash price now beats your copay. Say exactly this at the counter: "What would this cost if I didn't run it through insurance?" A fixed copay set last year can quietly exceed today's cash price on a matured generic. They can tell you. They generally have to be asked.
  • Call two other pharmacies with the drug name, strength, and quantity in hand. Markup is set per store. On a mature generic, that spread is the entire game.

The number was never the number

What you're actually recovering here isn't $50 a month. It's the assumption that a price you were quoted once is a fact about the world rather than a snapshot of one week in a market you weren't watching.

That's the thin, useful thing SnapRx does. You snap the label on the bottle you already have, and it shows you the fair national-average cash benchmark — the CMS NADAC figure, the same public number that tracks a generic falling off its cliff — alongside real pharmacies near you to call. No account, no card, no pitch. Just the typical number, so the one on your receipt has something to be measured against.

If the prescription in your cabinet has been the same price for three years, it might be worth thirty seconds to find out whether the world agrees. Take a look.